Author:
Magyar K.,Szatmáry I.,Szebeni G.,Lengyel J.
Reference33 articles.
1. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Martin J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–128
2. Carillo MC, Kanai S, Nokubo M, Kitani K (1991) (—)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidise in the striatum of young male rats. Life Sci 48: 517–521
3. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184: 119–126
4. Gaál J, Szebeni Gy, Székács G, Fejér E, Wágner Ö, Szatmári I, Magyar K, Mezei M (2000) Transdermal formulations of deprenyl: guinea pig and pig models. Neurobiology 8(2): 143–166
5. Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L (1999) Oral versus transdermal selegiline antidepressant-like activity in rats. Pharmacol Biochem Behav 63(3): 501–506
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献